Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 23OTHER 20NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 3Gastrointestinal 2Lymphoid 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Cisplatin 63Paclitaxel 56Carboplatin 38Taxes 24Radiotherapy 21Gemcitabine 16Brachytherapy 15Filgrastim 14Doxorubicin 13Topotecan 12Platinum 121,2-diaminocyclohexaneplatinum II citrate 12Docetaxel 11Radiation 7Granulocyte Colony-Stimulating Factor 7Chemotherapy, Adjuvant 7pegfilgrastim 6Surgical Procedures, Operative 6Radiotherapy, Intensity-Modulated 6Polymerase Chain Reaction 6Ifosfamide 6Etoposide 6Watchful Waiting 5Radiotherapy, Conformal 5Pemetrexed 5Gene Expression Profiling 5Fluorouracil 5Celecoxib 5Amifostine 5Observation 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Disulfides × Gynecologic × Clear all
NCT00886691 2022-02-04

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

GOG Foundation

Phase 2 Completed
150 enrolled 11 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡